Source comparison
BPC-157 + GHK-Cu: Protocol Comparison
Primary Mechanism VEGF receptor upregulation, angiogenesis MMP modulation, collagen remodeling Dual-phase targeting (vascular + structural) Complementary pathways maximize both closure speed and tissue quality Typical Dosing 250–500 mcg/day SC 1–3 mg/day topic
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF receptor upregulation, angiogenesis
- MMP modulation, collagen remodeling
- Dual-phase targeting (vascular + structural)
- Complementary pathways maximize both closure speed and tissue quality
- Typical Dosing
- 250–500 mcg/day SC
- 1–3 mg/day topical or SC
- BPC-157 500 mcg/day SC + GHK-Cu 2 mg/day topical
- Split-route administration avoids peptide interaction at injection site
- Onset of Visible Effect
- 5–7 days (granulation tissue formation)
- 10–14 days (scar texture improvement)
- 3–5 days (accelerated closure + early remodeling)
- Stacking shortens lag phase by initiating both processes concurrently
- Scar Quality (Collagen Alignment Score)
- Moderate (60–70% alignment vs normal skin)
- High (80–85% alignment)
- Very High (85–92% alignment)
- GHK-Cu prevents the disorganized matrix deposition BPC-157 alone can produce
- Cost Per 30-Day Cycle
- $80–$120 (5 mg vial)
- $60–$90 (30 mg vial)
- $140–$210 combined
- Higher upfront cost justified by reduced healing time and revision rates